EMulate Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- EMulate Therapeutics's estimated annual revenue is currently $2.1M per year.
- EMulate Therapeutics's estimated revenue per employee is $98,000
Employee Data
- EMulate Therapeutics has 21 Employees.
EMulate Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Corporate Secretary and Sr. VP, General Counsel | Reveal Email/Phone |
2 | VP, Investor Relations and Education | Reveal Email/Phone |
3 | Chief Regulatory Officer | Reveal Email/Phone |
4 | Director, Pre-Clinical | Reveal Email/Phone |
5 | Executive Assistant to the CEO/Office Manager | Reveal Email/Phone |
6 | President, CEO & Chairman the Board | Reveal Email/Phone |
EMulate Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $14.1M | 101 | 5% | N/A | N/A |
#2 | $1.6M | 19 | -71% | N/A | N/A |
#3 | $212.8M | 1063 | 5% | $65M | N/A |
#4 | $6.8M | 54 | 8% | N/A | N/A |
#5 | $12.9M | 92 | 2% | $23.1M | N/A |
#6 | $1M | 12 | N/A | N/A | N/A |
#7 | $106.5M | 599 | -17% | $2.3M | N/A |
#8 | $35.6M | 231 | 6% | N/A | N/A |
#9 | $38.3M | 249 | 5% | N/A | N/A |
#10 | $45M | 299 | -4% | $102.6M | N/A |
What Is EMulate Therapeutics?
N/A
Total Funding
21
Number of Employees
$2.1M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
EMulate Therapeutics News
2022-04-06 - Medikine to Highlight Preclinical Data on its Lead Program ...
... unrelated to, the natural cytokine proteins they emulate. ... and infectious disease therapeutics by employing a disruptive and...
2022-03-30 - 10 ways COVID-19 rocked biotechplus an honorable ...
The pandemic turned R&D on its head as many biopharmas rushed to develop therapeutics and vaccines to varying levels of success.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.7M | 21 | -9% | N/A |
#2 | $2.1M | 21 | 5% | N/A |
#3 | $2.1M | 21 | 5% | N/A |
#4 | $2.1M | 21 | -30% | N/A |
#5 | N/A | 21 | -50% | N/A |